RSRanran Shi

Ranran Shi

*This is an algorithmically generated author record based on publicly available information.

Ranran Shi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Guodong Li

    School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China

    1 shared publication
  • Ling Ran

    Henan Province Engineering and Technology Research Center of Foods for Special Medical Purpose , Luohe Medical College , Luohe 462000 , China , lhmc.edu.cn

    1 shared publication
  • Tiantian Song

    Henan Province Engineering and Technology Research Center of Foods for Special Medical Purpose , Luohe Medical College , Luohe 462000 , China , lhmc.edu.cn

    1 shared publication
  • Wenwen Liu

    School of Life Sciences Zhengzhou University Zhengzhou 450001 China zzu.edu.cn

    1 shared publication
  • Xiaowen Zhou

    School of Life Sciences , Zhengzhou University , Zhengzhou 450001 , China , zzu.edu.cn

    1 shared publication
  • Xiuman Zhou

    School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China

    1 shared publication

Latest Publications

  • Open Access

    Cancer‐Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives

    by Ranran Shi, Ling Ran, Tiantian Song, Xiaowen Zhou, Wenshan Zhao, Yijie Zhang

    Cancer‐testis antigens (CTAs) represent a unique class of tumor‐associated antigens (TAAs) with highly restricted expression in immune‐privileged tissues and widespread aberrant activation in various malignancies. Their potent immunogenicity and tumor specificity make CTAs promising targets for cancer immunotherapy. This review provides a comprehensive overview of the molecular regulation, biological functions, and therapeutic applications of CTAs. We detail the genetic and epigenetic mechanisms that drive CTA expression in cancer, their roles in tumor progression, and their capacity to elicit robust CD8 + T cell responses. Recent clinical advances in peptide‐ and dendritic cell–based vaccines, T‐cell receptor (TCR)‐engineered adoptive cell therapies, and combination strategies with immune checkpoint inhibitors (ICIs) are highlighted, emphasizing NY‐ESO‐1 and MAGE family antigens as leading candidates. We further discuss the major challenges limiting clinical translation, emphasizing that despite promising immunogenicity, most CTA‐directed modalities remain in early clinical evaluation with heterogeneous response rates, intratumoral heterogeneity, antigen loss, and risks of off‐target toxicity. The review also explores emerging approaches—such as epigenetic modulators, multiantigen targeting, and CRISPR‐based gene editing—that aim to enhance the precision and efficacy of CTA‐based immunotherapies. Together, these insights underscore the strategic potential of CTAs in next‐generation immunotherapy and outline the future directions required to bring these promising agents from bench to bedside.

  • Open Access

    Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis

    by Yan Lin, Yu Dong, Yanfeng Gao, Ranran Shi, Yubing Li, Xiuman Zhou, Wenwen Liu, Guodong Li, Yuanming Qi, Yahong Wu

    Tuberculosis is the worlds most deadly infectious disease, with 10 million people falling ill and 1.5 million people dying from the disease every year. With the increasing number of drug-resistant Mycobacterium tuberculosis (MTB) strains and prevalence of coinfection of MTB with human immunodeficiency virus, many challenges remain in the prevention and treatment of tuberculosis. Therefore, the development of safe and effective tuberculosis vaccines is an urgent issue. In this study, we identified cytotoxic T lymphocyte epitopes on drug resistance-associated membrane protein efflux pumps of MTB, the ATP-binding cassette and the major facilitator superfamilies. First, three online software were used to predict HLA-A2-restricted epitopes. Then, the candidate epitopes were confirmed with the T2A2 cell binding affinity and peptide/MHC (pMHC) complex stability assays and in vitro immune activity experiments. Two drug-resistant T lymphocyte epitopes, designated Rv1218c-p24 and Rv2477c-p182, were selected, and their immunogenic activities studied in vivo in genetically engineered mice. The immune activities of these two epitopes were improved with the help of complete Freunds adjuvant (CFA). The epitopes identified here provide a foundation for the diagnosis and treatment of patients infected with drug resistant and the future development of a multiepitope vaccine.